Guess how much NIB shares have gained since Medibank's cyber attack?

NIB's shares have been outperforming Medibank's by some distance since the hack…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares are pushing higher again on Monday.

At the time of writing, the private health insurer's shares are up almost 1% to $7.20.

This adds to the decent gains NIB's shares have made since the Medibank Private Ltd (ASX: MPL) cyber incident became public.

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

How much have NIB's shares risen since the incident?

First things first, the NIB share price actually sank 12% on the day that Medibank's hack was announced.

However, that was primarily due to the company raising $150 million to support its expansion into the NDIS market.

NIB raised the funds at $6.90 per new share, which represents an 8.1% discount to its last close price.

So, if we take this out of the equation, you could argue that the NIB share price fell 3.9% in response to news of Medibank's hack. Investors may have feared that the hackers could have infiltrated their systems as well. But this ultimately wasn't the case.

So, after accounting for the capital raising, the NIB share price has gained somewhere in the region of 4.5% since the incident. Whereas the Medibank share price has gone the other way and lost almost 20% of its value since the hack was announced.

That's a relative outperformance of approximately 24% for NIB's shares. I know which private health insurer I would've wanted in my portfolio!

Can its shares keep rising?

The good news for investors is that one leading broker believes the NIB share price can keep rising.

According to a note out of Morgans, its analysts have retained their add rating with an improved price target of $8.54. This implies potential upside of almost 19% for investors over the next 12 months.

Morgans was impressed with the company's strong start to FY 2023 and has been forced to upgrade its earnings estimates to reflect this. It explained:

We lift NHF FY23F/FY24F EPS by 11%/2% reflecting more favorable underlying growth trends than expected and also a lift to investment income assumptions. Our PT rises marginally to A$8.54 (previously A$8.27).

Overall, the broker believes NIB's outlook is positive and its shares are trading at an attractive level. It concludes:

NHF is a well-run company, and the near-term operating environment remains favourable for its key Australian Residential Health Insurance business (assisted by a benign claims environment). Covid-19 headwinds that were affecting some of NIB's other businesses, e.g. IIHI and Travel etc. also appear to be easing. With NIB trading at a >10% discount to our target price, we maintain our ADD call.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Lab worker puts hands in the air and dances around.
Healthcare Shares

CSL shares look primed to take off — Here's why

Business remains robust and brokers see ASX stock soaring up to 100%.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »